Stoke Therapeutics — Third Quarter 2026 Earnings Summary

Stoke Therapeutics reported a net loss of $73.6 million for the third quarter of 2026, driven by increased research and development expenses to advance its lead candidate zorevunersen. The company's Phase 3 EMPEROR study for Dravet syndrome has completed enrollment of 162 patients in key regions, with a data readout anticipated in the third quarter of 2027. Additionally, the Phase 1 OSPREY study for the investigational drug STK-002 targeting Autosomal Dominant Optic Atrophy is ongoing, with initial safety and efficacy data expected in the first half of 2027. As of September 30, 2026, Stoke held $358.8 million in cash and marketable securities, which is projected to fund operations into early 2028.